Abstract 1309
Background
Organized cervical cancer screening program for women aged 30 or over using Pap Smear has been launched in Korea since 1999. However, there is limited evidence showing the effectiveness of this nationwide screening program in reducing cervical cancer mortality. In this study, we aim to examine cervical cancer mortality among screened and non-screened women who participated in the Korean National Cancer Screening Program (KNCSP) from 2002 to 2003.
Methods
We conducted a prospective cohort study of women aged 30-79 years invited to the KNCSP between 2002 - 2003 and followed up to 2015 for deaths from cervical cancer and other causes. Women with incomplete ID, diagnosed with cervical cancer before entering the cohort, or older than 79 years were excluded. Finally, a total of 8,262,267 women aged 30-79 were included, and their cervical cancer screening exposure, cancer incidence, and death information were collected from the KNCSP database, National Cancer Registry, and death certificate from Statistics Korea. There were 6,615,614 women in the screen group (mean person-year: 9.74) and 5,814,989 women in the non-screen group (mean person-year: 8.33). Incidence rate ratio (IRR) and Mortality rate ratio (MRR) were used to compare between screen and non-screen cohorts using Poisson regression model. The MRRs and IRRs were adjusted for age at inclusion in the cohort, insurance type, and self-selection bias.
Results
The crude mortality rate was 3.49 and 8.77 per 100,000 women-years for screen and non-screen group, respectively. MRR for cervical cancer was 0.46 (95% confidence interval (CI): 0.44-0.48). After adjusting for self-selection bias, it was estimated that there was 36.11% of mortality reduction in screen group compared to non-screen group. Also, IRR of invasive cancer in screen group was 0.74 (95% CI: 0.72-0.76) compared to non-screen group. However, there was no significant reduction in the total number of invasive cervical cancer and cervical cancer in situ incidence rate (IRR: 0.98; 95%CI: 0.98 (0.96-1.00)).
Conclusions
We found that after 13 years of follow-up, 36.11% of cervical cancer mortality reduction was observed among women who attended the Korean National Cervical Cancer Screening Program.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kui Son Choi.
Funding
National Cancer Center, Korea (Grant number: 1610401) and International Cooperation & Education Program (NCCRI·NCCI 52210-52211,2019) of National Cancer Center, Korea.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3180 - Genomic analysis of hepatobiliary lithiasis associated cholangiocarcinoma revealed a distinct subtype feature.
Presenter: Lunda Gu
Session: Poster Display session 2
Resources:
Abstract
4891 - Comparison of the impact of stereotactic body radiation therapy vs. radiofrequency ablation on liver function in patients with single hepatocellular carcinoma: A propensity score matching analysis
Presenter: Masayuki Ueno
Session: Poster Display session 2
Resources:
Abstract
3203 - Exploratory analysis based on tumor location and early metabolic tumor response of REACHIN, a randomized double-blinded placebo-controlled phase II trial of regorafenib after failure of gemcitabine/platinum-based chemotherapy for advanced and metastatic biliary tract tumors.
Presenter: Anne Demols
Session: Poster Display session 2
Resources:
Abstract
1602 - Predictive Value of Neutrophil-Lymphocyte Ratio (NLR) And Platelet-Lymphocyte Ratio (PLR) In Hepatocellular Carcinoma (HCC) Patients Treated with Nivolumab (N)
Presenter: Sirish Dharmapuri
Session: Poster Display session 2
Resources:
Abstract
2848 - Preliminary Safety and Pharmacokinetics of a New Lysosomotropic Oral Agent, GNS561, in a First-in-Human Study in Advanced Primary Liver Cancer Patients
Presenter: Ahmad Awada
Session: Poster Display session 2
Resources:
Abstract
1396 - A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): updated results
Presenter: Josep Llovet
Session: Poster Display session 2
Resources:
Abstract
1139 - Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in HCC patients treated with sorafenib: Final results of INNOVATE study
Presenter: Andrea Casadei-gardini
Session: Poster Display session 2
Resources:
Abstract
4688 - Prognostic and predictive factors from the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Presenter: Tim Meyer
Session: Poster Display session 2
Resources:
Abstract
1492 - A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL.
Presenter: David Pinato
Session: Poster Display session 2
Resources:
Abstract
3159 - Anlotinib for advanced hepatocellular carcinoma: interim results from the phase II ALTER0802 study
Presenter: AiPing Zhou
Session: Poster Display session 2
Resources:
Abstract